3月19日,和黄医药公告了2024年年报。财报显示,和黄医药2024年实现综合收入6.302亿美元,同比下滑24.8%,应占净收益为3770万美元,而2023年则为1.008亿美元。尽管综合收入和净收益有所下滑,但其肿瘤药物销售依旧强劲。2024年,肿瘤产品市场销售额增长134%至5.01亿美元。得益于此,肿瘤产品综合收入强劲增长65%至2.715亿美元。如此业绩表现,离不开和黄医药早早开启的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.